COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series.
Adverse event
COVID-19
Guillain-Barré syndrome
Peripheral nervous system
Prognosis
SARS-CoV-2
Vaccination
Journal
Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403
Informations de publication
Date de publication:
15 09 2022
15 09 2022
Historique:
received:
25
03
2022
revised:
07
06
2022
accepted:
21
06
2022
pubmed:
9
7
2022
medline:
9
9
2022
entrez:
8
7
2022
Statut:
ppublish
Résumé
Guillain-Barré-Syndrome (GBS) can follow COVID-19 vaccination, with clinical and paraclinical features still to be precisely assessed. We describe a cohort of patients who developed GBS after vaccination with different types of COVID-19 vaccines. Patients with post-COVID-19 vaccination GBS, admitted to the six hospitals that cover the whole Liguria Region, Northwestern Italy, from February 1st to October 30th 2021, were included. Clinical, demographic, and paraclinical data were retrospectively collected. Among the 13 patients with post-COVID-19 vaccination GBS (9 males; mean age, 64 year), 5 were vaccinated with Oxford-AstraZeneca, 7 with Pfizer-BioNTech, and one with Moderna. Mean time between vaccination and GBS onset was 11.5 days. Ten patients developed GBS after the first vaccination dose, 3 after the second dose. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) was the predominant GBS variant, mainly characterized by sensory involvement. Bilateral seventh cranial nerve involvement followed AstraZeneca vaccination in two cases. Three patients presented treatment-related fluctuations, and 4 mild symptoms that delayed treatments and negatively affected prognosis. Prognosis was poor (GBS-disability score, ≥3) in 5/13 patients, with a disability rate of 3/13. Our findings confirm that most post-COVID-19 vaccination GBS belong to the AIDP subtype, and occur after the first vaccine dose. Treatment-related fluctuations, and diagnosis-delaying, mild symptoms at onset are clinical features that affect prognosis and deserve particular consideration.
Sections du résumé
BACKGROUND AND PURPOSE
Guillain-Barré-Syndrome (GBS) can follow COVID-19 vaccination, with clinical and paraclinical features still to be precisely assessed. We describe a cohort of patients who developed GBS after vaccination with different types of COVID-19 vaccines.
METHODS
Patients with post-COVID-19 vaccination GBS, admitted to the six hospitals that cover the whole Liguria Region, Northwestern Italy, from February 1st to October 30th 2021, were included. Clinical, demographic, and paraclinical data were retrospectively collected.
RESULTS
Among the 13 patients with post-COVID-19 vaccination GBS (9 males; mean age, 64 year), 5 were vaccinated with Oxford-AstraZeneca, 7 with Pfizer-BioNTech, and one with Moderna. Mean time between vaccination and GBS onset was 11.5 days. Ten patients developed GBS after the first vaccination dose, 3 after the second dose. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) was the predominant GBS variant, mainly characterized by sensory involvement. Bilateral seventh cranial nerve involvement followed AstraZeneca vaccination in two cases. Three patients presented treatment-related fluctuations, and 4 mild symptoms that delayed treatments and negatively affected prognosis. Prognosis was poor (GBS-disability score, ≥3) in 5/13 patients, with a disability rate of 3/13.
CONCLUSIONS
Our findings confirm that most post-COVID-19 vaccination GBS belong to the AIDP subtype, and occur after the first vaccine dose. Treatment-related fluctuations, and diagnosis-delaying, mild symptoms at onset are clinical features that affect prognosis and deserve particular consideration.
Identifiants
pubmed: 35802961
pii: S0022-510X(22)00192-7
doi: 10.1016/j.jns.2022.120330
pmc: PMC9232395
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
120330Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
Neurology. 1999 Feb;52(3):635-8
pubmed: 10025803
J Peripher Nerv Syst. 2017 Jun;22(2):68-76
pubmed: 28406555
Ann Neurol. 2022 Mar 2;:
pubmed: 35233819
Muscle Nerve. 2022 Feb;65(2):233-237
pubmed: 34786740
J Neurol. 2021 Apr;268(4):1133-1170
pubmed: 32840686
Clinics (Sao Paulo). 2021 Oct 11;76:e3286
pubmed: 34644738
J Neurol Sci. 2020 Nov 15;418:117114
pubmed: 32947089
Ann Neurol. 1998 Nov;44(5):780-8
pubmed: 9818934
Nature. 2021 Aug;596(7873):495-504
pubmed: 34237771
Ann Neurol. 2021 Aug;90(2):312-314
pubmed: 34114256
J Neuroimmunol. 2021 Oct 15;359:577691
pubmed: 34416410
Ann Neurol. 2021 Aug;90(2):315-318
pubmed: 34114269
N Engl J Med. 2012 Jun 14;366(24):2294-304
pubmed: 22694000
Neurology. 2021 Apr 6;:
pubmed: 33824169
Muscle Nerve. 1991 Nov;14(11):1103-9
pubmed: 1745285
Brain. 2021 Mar 3;144(2):682-693
pubmed: 33313649
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1144-1151
pubmed: 34362855
J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):957-60
pubmed: 1800666
J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1157-63
pubmed: 20870864
Ann Neurol. 1990;27 Suppl:S21-4
pubmed: 2194422
Front Neurol. 2022 Jan 27;12:820723
pubmed: 35153993